CRP and familial pancreatic carcinoma: CRP was the most frequently assessed marker of inflammation, most often in advanced or palliative cancer patients, where it was observed that capsule/oral n-3 supplementation decreased CRP in head and neck [18], lung [40,52,54], gastrointestinal [27,40,64], or pancreatic [64] cancers or maintained CRP levels during n-3 supplementation in breast [12,13], lung [50] or pancreatic cancer [57] compared to either baseline levels or increased CRP in non-supplemented controls (Supplementary Materials, Table S1).